Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rafarma Pharmaceuticals, Inc. (RAFA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.7000-0.0250 (-3.45%)
At close: 03:41PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear Research

    Nicosia, Cyprus, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is currently negotiating with the Joint Institute for Nuclear Research (JINR), an international intergovernmental scientific organization established by eleven founding countries in 1956 and registered by the United Nations. The purpose of the current negotiations is the development and implementation of Rafarma Pharmaceuticals’ projects related to nuclear medicine technologies, radiopharmaceuticals, radi

  • GlobeNewswire

    RAFA To Add Major Component to the Tashkent Pharma Park

    Nicosia, Cyprus, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) and the Czech company “Block” signed an agreement on the implementation of the construction of a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park in Uzbekistan. The new partner of the promising project is the multinational engineering group BLOCK with a unique specialization and experience in the field of healthcare and pharmacology. The interests of Rafarma in this agree

  • GlobeNewswire

    Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5

    Nicosia, Cyprus, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019. Specifically, Kraspharma went from $5,563,056 (USD) at the end of 2019 to $17,853,905 at the end of 2020. The growth was featured in the ratings by the authoritative Russian indu

Advertisement
Advertisement